AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01403948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
Study NCT04957433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Specimen
Description: Blood and Sputum Specimen Samples
Study NCT02991989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Snacking
Description: Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours.
Study NCT02471157 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT03104842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Antibody Intravenous
Study NCT03104842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous
Study NCT03104842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsel
Study NCT03104842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Capsel
Study NCT02536287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total PTX without autotransplantation
Description: All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
Study NCT02536287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total PTX with autotransplantation
Description: All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1\*1 \*1 mm,and placed into the subcutaneous of the forearm.
Study NCT03235687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ExoDx Prostate (IntelliScore)
Description: ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
Study NCT01278576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX-A®
Description: 200 units, single treatment only
Study NCT01278576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX-A®
Description: 200 units, single treatment only
Study NCT01451619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laropiprant
Description: One 100-mg tablet orally once daily for 4 weeks
Study NCT01451619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Laropiprant
Description: One tablet orally once daily for 4 weeks
Study NCT01369121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XERECEPT
Description: BID dosing, subcutaneous for 1 year
Study NCT01403909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Description: Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
Study NCT01403909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
Study NCT02336477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: * Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~* Patients will receive gradual dose of the treatment as it would be done in clinical practice.~* Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~* The duration of each treatment period is 18 days minimum (maximum 22 days).
Study NCT02336477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02898480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
Study NCT01246206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Thymoglobulin
Description: Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.
Study NCT04226313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-sampling by Evalyn Brush
Description: Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
Study NCT04226313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampling by Evalyn Brush
Description: Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
Study NCT04226313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self sampling by Evalyn Brush home or in GP´s clinic
Description: Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
Study NCT02943395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement
Study NCT02943395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement
Study NCT02991989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
Study NCT02991989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Yogurt
Description: Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
Study NCT00749814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
Study NCT00749814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo
Study NCT00866099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Dementia training
Description: Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified.
Study NCT00936169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS optimised DES implantation
Description: Ivus optimised stent implantation
Study NCT00936169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angiographically guided DES implantation
Description: angiographically guided DES implantation
Study NCT01961973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cultured Chondrocytes
Description: This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
Study NCT02057588 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LV pacing site
Description: Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
Study NCT03121976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Femoral catheter inserted using ultrasound only
Study NCT03121976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound + Nerve Stimulation
Description: Femoral catheter inserted using ultrasound and nerve stimulation
Study NCT01109732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic physical training with instructor
Description: Training 3 times per week for 6 months, the first 3 months with an instructor
Study NCT00619320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safer Sex Skills Building (SSB)
Description: Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
Study NCT01961973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cultured BMAC
Description: This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
Study NCT00619320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Sex Skills Building (SSB)
Description: Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
Study NCT01317108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF Chemotherapy
Study NCT01982968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Full fundoplication surgery for the treatment of abnormal GER
Study NCT00729469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Description: 60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
Study NCT00262223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seeking Safety
Description: Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
Study NCT00262223 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Seeking Safety
Description: Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
Study NCT00262223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
Study NCT00262223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pill placebo
Study NCT00493142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00729469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
Study NCT01998568 — intervention group
Intervention type: OTHER
Intervention: Intraocular pressure measurement
Description: Using different tonometers for intraocular pressure measurement
Study NCT02219802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment according arm
Study NCT02219802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment according arm
Study NCT01455909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 60 mcg/day
Description: exenatide in DUROS
Study NCT01455909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: sitagliptin oral 100 mg/day
Study NCT03459690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Isha Kriya meditation is simple meditation practice which can be easily learned by employing online guided tools. Isha Kriya meditation requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. Isha Kriya does not incorporate a spiritual or religious focus.
Study NCT03459690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enobio 32- EEG machine
Description: This study utilizes the Enobio 32 EEG device made by Neuroelectrics (an FDA-cleared 24-bit EEG data reader which is a wearable wireless device) to analyze EEG changes after subjects have undergone meditation. This study does not evaluate the Enobio device, and the IRB of record approved an Investigational Device Exemption for this study.
Study NCT03463070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rectal misoprostol 600mg
Description: 70 women who received 600 mg misoprostol postoperatively at operating theatre
Study NCT03806426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid free fatty acid (EPA-FFA)
Description: 500mg capsule, two 500mg capsules to be taken twice daily for 24 months
Study NCT03806426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500mg capsule, two 500mg capsules to be taken twice daily for 24 months
Study NCT03524573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Appendectomy
Description: Appendectomy is the surgical removal of the appendix.
Study NCT03524573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Appendectomy is the surgical removal of the appendix.
Study NCT02273245 — intervention group
Intervention type: RADIATION
Intervention: Thoracic aortogram CT
Description: With and without contrast dye
Study NCT04061083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Cuff Manager
Description: Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
Study NCT04061083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manometer
Description: Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
Study NCT00649454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide and Metformin HCl Tablets 5 mg/500 mg
Description: 5/500mg, single dose fasting
Study NCT00649454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaglip® Tablets 5 mg/500 mg
Description: 5/500mg, single dose fasting
Study NCT04752202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individually balanced elimination/reducing diets
Description: Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
Study NCT04752202 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individually balanced reducing diets (without elimination)
Description: Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
Study NCT00834054 — intervention group
Intervention type: PROCEDURE
Intervention: Double-lung transplantation
Description: Double-lung transplanted patients
Study NCT03067090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamid Reconstruction
Description: AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle.
Study NCT03388593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: 10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
Study NCT03388593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Study NCT00943995 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: somatropin
Description: 0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
Study NCT02822456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VFSS
Description: VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
Study NCT02822456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VFSS
Description: VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
Study NCT00362973 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT01794195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging and fibres tracking
Study NCT00493142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT00362973 — intervention group
Intervention type: PROCEDURE
Intervention: needle biopsy